IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
TheFly reported on April 14 that Wedbush Securities increased its price target on IDYA from $52 to $58 while maintaining an Outperform rating. The update followed the company's release of top-line results from its Phase 2/3 OptimUM-02 clinical trial. Management reported that safety outcomes remain consistent with earlier studies, with adverse events generally manageable. The firm also noted that additional detailed findings from the study are expected to be shared at a major medical conference in 2026, which could provide further clarity on the program's clinical profile and future development potential. Adding to the company's operational momentum, on April 6, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported that it has begun patient enrollment in a Phase 1 dose-escalation study of IDE574, a first-in-class oral small-molecule therapy designed to inhibit KAT6 and KAT7, two epigenetic targets involved in cancer cell survival. IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma [YaYa
- IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma [ThTh
- IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal MelanomaPR Newswire
- IDEAYA Biosciences (IDYA) had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "neutral" rating on the stock.MarketBeat
- IDEAYA Biosciences (IDYA) had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.MarketBeat
IDYA
Earnings
- 2/17/26 - Beat
IDYA
Sec Filings
- 4/13/26 - Form 8-K
- 4/9/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- IDYA's page on the SEC website